Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Cash from Financing Activities: 2013-2024

Historic Cash from Financing Activities for Wave Life Sciences (WVE) over the last 12 years, with Dec 2024 value amounting to $253.9 million.

  • Wave Life Sciences' Cash from Financing Activities fell 83.95% to $32.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.5 million, marking a year-over-year decrease of 73.30%. This contributed to the annual value of $253.9 million for FY2024, which is 91.57% up from last year.
  • As of FY2024, Wave Life Sciences' Cash from Financing Activities stood at $253.9 million, which was up 91.57% from $132.5 million recorded in FY2023.
  • Wave Life Sciences' 5-year Cash from Financing Activities high stood at $253.9 million for FY2024, and its period low was $55.8 million during FY2021.
  • For the 3-year period, Wave Life Sciences' Cash from Financing Activities averaged around $151.2 million, with its median value being $132.5 million (2023).
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first plummeted by 63.87% in 2021, then skyrocketed by 97.26% in 2023.
  • Yearly analysis of 5 years shows Wave Life Sciences' Cash from Financing Activities stood at $154.5 million in 2020, then plummeted by 63.87% to $55.8 million in 2021, then increased by 20.35% to $67.2 million in 2022, then soared by 97.26% to $132.5 million in 2023, then surged by 91.57% to $253.9 million in 2024.